The inflammatory response in myocardial injury, repair, and remodelling.
TLDR
Biomarker-based approaches are needed to identify patients with distinct pathophysiologic responses and to rationally implement inflammation-modulating strategies in patients with myocardial infarction.Abstract:
Myocardial infarction triggers an intense inflammatory response that is essential for cardiac repair, but which is also implicated in the pathogenesis of postinfarction remodelling and heart failure. Signals in the infarcted myocardium activate toll-like receptor signalling, while complement activation and generation of reactive oxygen species induce cytokine and chemokine upregulation. Leukocytes recruited to the infarcted area, remove dead cells and matrix debris by phagocytosis, while preparing the area for scar formation. Timely repression of the inflammatory response is critical for effective healing, and is followed by activation of myofibroblasts that secrete matrix proteins in the infarcted area. Members of the transforming growth factor β family are critically involved in suppression of inflammation and activation of a profibrotic programme. Translation of these concepts to the clinic requires an understanding of the pathophysiological complexity and heterogeneity of postinfarction remodelling in patients with myocardial infarction. Individuals with an overactive and prolonged postinfarction inflammatory response might exhibit left ventricular dilatation and systolic dysfunction and might benefit from targeted anti-IL-1 or anti-chemokine therapies, whereas patients with an exaggerated fibrogenic reaction can develop heart failure with preserved ejection fraction and might require inhibition of the Smad3 (mothers against decapentaplegic homolog 3) cascade. Biomarker-based approaches are needed to identify patients with distinct pathophysiologic responses and to rationally implement inflammation-modulating strategies.read more
Citations
More filters
Journal ArticleDOI
Protective role of ErbB3 signaling in myeloid cells during adaptation to cardiac pressure overload.
Haifeng Yin,Amanda J. Favreau-Lessard,Joanne T. deKay,Yodit R. Herrmann,Michael P. Robich,Robert A. Koza,Igor Prudovsky,Douglas B. Sawyer,Sergey Ryzhov +8 more
TL;DR: The crucial role of myeloid cell-specific ErbB3 signaling in the cardiac accumulation ofMyeloid cells, which contributes to the activation of cardiac endothelial cells and fibroblasts and development of an early adaptive response to cardiac pressure overload in male mice is demonstrated.
Journal ArticleDOI
Application of curcumine and its derivatives in the treatment of cardiovascular diseases: a review
Mimoza Stamenkovska,Nikola Hadzi-Petrushev,Aleksandar Nikodinovski,Hristo Gagov,Natalija Atanasova-Panchevska,V.M. Mitrokhin,Andre Kamkin,Mitko Mladenov +7 more
TL;DR: The potential and possibilities of using curcumin and its derivatives in the treatment of cardiovascular disease, which would significantly reduce the mortality rate in the population are reviewed.
Journal ArticleDOI
Receptor for activated C kinase 1 in rats with ischemia-reperfusion injury: intravenous versus inhalation anaesthetic agents.
TL;DR: There were significant differences in inflammation and apoptosis, including the expression of RACK1 and TLR4, after myocardial IRI between the propofol and isoflurane groups, however, both groups had similar heart injury scores.
Journal Article
Evaluation of cardiac microvasculature in patients with diffuse myocardial fibrosis.
Octavian Istrătoaie,Ionica Pirici,Anca Maria Ofiţeru,Florin Grosu,Alice Brinzea,Lavinia Olar,Ion Cristian Efrem +6 more
TL;DR: Myocardial microvascular density evaluation of the patients with high blood pressure, atrial fibrillation, coronary heart disease, and heart failure showed a significant decrease of the values of this parameter, which means that myocardial fibrosis is the direct result of stimulation of myocardia fibroblasts induced by local hypoxia.
Journal ArticleDOI
Sequential transplantation of exosomes and mesenchymal stem cells pretreated with a combination of hypoxia and Tongxinluo efficiently facilitates cardiac repair
Yu-Yan Xiong,Rui-Jie Tang,Jun Xu,Wen-Yang Jiang,Zhaoting Gong,Lili Zhang,Xiaosong Li,Yu Ning,Pei-Sheng Huang,Gui-Hao Chen,Chen Jin,Xiangdong Li,H. Qian,Yuejin Yang +13 more
TL;DR: In this article , the authors explored the therapeutic efficacy of sequential transplantation of exosomes and combinatorial pretreated MSCs in the treatment of acute myocardial infarction (AMI).
References
More filters
Journal ArticleDOI
Getting to the site of inflammation: the leukocyte adhesion cascade updated
TL;DR: This Review focuses on new aspects of one of the central paradigms of inflammation and immunity — the leukocyte adhesion cascade.
Journal ArticleDOI
DAMPs, PAMPs and alarmins: all we need to know about danger
TL;DR: The term “alarmin” is proposed to categorize such endogenous molecules that signal tissue and cell damage, and can be considered subgroups of a larger set, the damage‐associated molecular patterns (DAMPs).
Journal ArticleDOI
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.
Harvey D. White,R M Norris,Michael A. Brown,Peter W.T. Brandt,Ralph M.L. Whitlock,Chris J. Wild +5 more
TL;DR: Volume, ejection fractions, and severity of coronary arterial occlusions and stenoses in 605 male patients under 60 years of age at 1 to 2 months after a first or recurrent myocardial infarction showed that end-systolic volume had greater predictive value for survival than end-diastolic volume or ejection fraction.
Journal ArticleDOI
Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling
TL;DR: Left ventricular end-diastolic and end-systolic volume and ejection fraction data provide support for the beneficial effects of therapeutic agents such as angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking agents on the remodeling process.
Related Papers (5)
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more